| 3.575 -0.805 (-18.38%) | 03-12 14:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.77 |
1-year : | 5.34 |
| Resists | First : | 4.08 |
Second : | 4.57 |
| Pivot price | 4.18 |
|||
| Supports | First : | 3.28 |
Second : | 2.73 |
| MAs | MA(5) : | 4.08 |
MA(20) : | 4.12 |
| MA(100) : | 3.72  |
MA(250) : | 3.3 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.6 |
D(3) : | 51.9 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 4.94 | Low : | 1.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RPID ] has closed below the lower bollinger band by 17.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ RPID ] is to continue within current trading range. Bollinger Bands are 25.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.47 - 4.51 | 4.51 - 4.53 |
| Low: | 4.03 - 4.07 | 4.07 - 4.09 |
| Close: | 4.34 - 4.39 | 4.39 - 4.43 |
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Thu, 12 Mar 2026
Rapid Micro Biosystems secures Samsung Biologics order - Investing.com Nigeria
Thu, 12 Mar 2026
RPID: Record Q4 revenue and major orders set the stage for strong 2026 growth and margin expansion - TradingView
Thu, 12 Mar 2026
RPID: Record revenue growth and major system orders signal accelerating adoption and improved outlook - TradingView
Thu, 12 Mar 2026
Rapid Micro Biosystems Reports Record Fourth Quarter and - GlobeNewswire
Thu, 12 Mar 2026
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct Platform - Bitget
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 40 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 10.3 (%) |
| Held by Institutions | 59.3 (%) |
| Shares Short | 178 (K) |
| Shares Short P.Month | 179 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | -145.2 % |
| Operating Margin | -145.1 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -68.9 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.76 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -3.58 |
| PEG Ratio | 0 |
| Price to Book value | 3.57 |
| Price to Sales | 4.67 |
| Price to Cash Flow | -3.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|